Hyuga Primary Care Co Ltd

Hyuga Primary Care Co Ltd maintains a debt-to-equity ratio of 1.7, indicating a moderate reliance on debt financing relative to equity. The company's current ratio of 1.21 suggests it has sufficient short-term assets to cover its short-term liabilities, though the margin is narrow. With cash and equivalents of 688,010,000 JPY and long-term debt of 2,798,550,000 JPY, the firm's net cash position is negative, raising concerns about liquidity risk. Profitability metrics for Hyuga Primary Care Co Ltd show a return on invested capital (ROIC) that is below the industry median, indicating suboptimal capital efficiency. The company's operating cash flow of 706,641,000 JPY supports its operations, but capital expenditures of -233,439,000 JPY suggest ongoing investment in infrastructure or expansion. Margins are in line with industry norms, but the firm's ability to sustain or improve these metrics will depend on its cost management and pricing power. The company's revenue is concentrated in its domestic market, with no significant international exposure disclosed in the available data. This concentration increases vulnerability to local economic conditions and regulatory changes. No material segment breakdown is available, but the firm's operations are primarily focused on drug retailing. Outlook for the current fiscal year indicates a modest revenue growth trajectory, with analysts reporting last actual revenue of 9,984,800,000 JPY. The firm's capital expenditures suggest a cautious approach to expansion, with a focus on maintaining operational efficiency rather than aggressive growth. The company's liquidity risk is assessed as medium, with a low probability of dilution in the near term. Risk factors include the company's reliance on debt financing and the potential for margin compression due to competitive pressures in the drug retailing sector. The firm's liquidity position is a concern, as cash reserves are insufficient to cover long-term obligations. No significant dilution events are expected in the near term, and the company's capital structure remains relatively stable. Recent filings and transcripts do not indicate any material changes in the company's strategic direction or financial outlook. The firm continues to operate within its core drug retailing business, with no disclosed plans for diversification or major restructuring.